Pacific Biosciences of California Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St

March 19, 2025

Pacific Biosciences of California (NASDAQ:PACB) Full Year 2024 Results

Key Financial Results

Revenue: US$154.0m (down 23% from FY 2023).
Net loss: US$309.9m (loss widened by 1.0% from FY 2023).
US$1.13 loss per share.

earnings-and-revenue-history — NasdaqGS:PACB Earnings and Revenue History March 19th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Pacific Biosciences of California EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 15%.

Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are down 6.9% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 3 warning signs for Pacific Biosciences of California that you need to be mindful of.

If you're looking to trade Pacific Biosciences of California, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.